Edwards’ TAVR device in moderate aortic stenosis drew applause from meeting attendees, while Medtronic’s renal denervation ...

CEO Ivan Tornos did not attribute the company’s performance in knees to a broader market slowdown, as competitor Stryker did ...

Patients, providers and medtech firms submitted hundreds of comments to the Food and Drug Administration on how the agency ...

CEO Kevin Lobo said the slowdown in hip and knee procedures is tied to broader economic concerns. The outgoing CEO also ...

Abbott said it is facing pricing pressure and slower growth ahead of a planned coverage expansion for people with Type 2 diabetes. Competitor Dexcom, however, did not experience the same slowdown.

In a year where companies are grappling with cyberattacks, inflation and potential tariffs, Farrell, who is also CEO of Resmed, shared a bird’s eye view of the issues.

The testing service providers hope the legislation, which would reform the CMS’ reimbursement rate-setting process, can cross the finish line in Congress’ lame-duck session.

In July 2015, Abbott agreed to buy Tendyne for $225 million upfront and secured an option to acquire Cephea. Abbott CEO Robert Ford discussed that period on an earnings call in July, telling investors ...

Philips will pay 288 million euros to settle an investigation related to its recall of millions of sleep and respiratory ...

Medline identified a potential fire hazard involving the beds, hand control pendants, control boxes and motors. The bed's electrical components may overheat in certain conditions, including in ...